MX347505B - Terapia basada en proteína y diagnóstico de patalogía mediada por tau en la enfermedad de alzheimer. - Google Patents

Terapia basada en proteína y diagnóstico de patalogía mediada por tau en la enfermedad de alzheimer.

Info

Publication number
MX347505B
MX347505B MX2014003357A MX2014003357A MX347505B MX 347505 B MX347505 B MX 347505B MX 2014003357 A MX2014003357 A MX 2014003357A MX 2014003357 A MX2014003357 A MX 2014003357A MX 347505 B MX347505 B MX 347505B
Authority
MX
Mexico
Prior art keywords
tau
alzheimer
disease
protein
antibodies
Prior art date
Application number
MX2014003357A
Other languages
English (en)
Spanish (es)
Other versions
MX2014003357A (es
Inventor
Noväk Michal
Kovácech Branislav
Zilka Norbert
KONTSEKOVÁ Eva
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47216372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347505(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of MX2014003357A publication Critical patent/MX2014003357A/es
Publication of MX347505B publication Critical patent/MX347505B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
MX2014003357A 2011-09-19 2012-09-14 Terapia basada en proteína y diagnóstico de patalogía mediada por tau en la enfermedad de alzheimer. MX347505B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161536339P 2011-09-19 2011-09-19
US201261653115P 2012-05-30 2012-05-30
PCT/IB2012/002246 WO2013041962A1 (en) 2011-09-19 2012-09-14 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

Publications (2)

Publication Number Publication Date
MX2014003357A MX2014003357A (es) 2015-03-20
MX347505B true MX347505B (es) 2017-04-28

Family

ID=47216372

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005573A MX391157B (es) 2011-09-19 2012-09-14 Terapia basada en proteina y diagnostico de patologia mediada por tau en la enfermedad de alzheimer.
MX2014003357A MX347505B (es) 2011-09-19 2012-09-14 Terapia basada en proteína y diagnóstico de patalogía mediada por tau en la enfermedad de alzheimer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017005573A MX391157B (es) 2011-09-19 2012-09-14 Terapia basada en proteina y diagnostico de patologia mediada por tau en la enfermedad de alzheimer.

Country Status (30)

Country Link
US (5) US9518101B2 (OSRAM)
EP (2) EP3275461A1 (OSRAM)
JP (7) JP6253583B2 (OSRAM)
KR (3) KR102285743B1 (OSRAM)
CN (2) CN104185640B (OSRAM)
AU (3) AU2012311234B2 (OSRAM)
BR (1) BR112014006376B1 (OSRAM)
CA (1) CA2848346A1 (OSRAM)
CL (3) CL2014000679A1 (OSRAM)
CY (1) CY1119792T1 (OSRAM)
DK (1) DK2758433T3 (OSRAM)
ES (1) ES2656442T3 (OSRAM)
HR (1) HRP20180083T8 (OSRAM)
HU (1) HUE036177T2 (OSRAM)
IL (4) IL231201B (OSRAM)
LT (1) LT2758433T (OSRAM)
ME (1) ME03008B (OSRAM)
MX (2) MX391157B (OSRAM)
MY (1) MY183989A (OSRAM)
PL (1) PL2758433T3 (OSRAM)
PT (1) PT2758433T (OSRAM)
RS (1) RS56852B1 (OSRAM)
RU (2) RU2645259C2 (OSRAM)
SG (4) SG10201703771WA (OSRAM)
SI (1) SI2758433T1 (OSRAM)
SM (1) SMT201800109T1 (OSRAM)
TR (1) TR201800669T4 (OSRAM)
UA (2) UA115657C2 (OSRAM)
WO (1) WO2013041962A1 (OSRAM)
ZA (1) ZA201401333B (OSRAM)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826286C (en) * 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
MY171473A (en) 2012-07-03 2019-10-15 Univ Washington Antibodies to tau
US9567395B2 (en) 2012-08-16 2017-02-14 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
CN111569063A (zh) * 2013-11-27 2020-08-25 伊皮埃里安股份有限公司 治疗tau病变的方法
WO2015098963A1 (ja) * 2013-12-26 2015-07-02 東亞合成株式会社 カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
SG11201610446XA (en) * 2014-06-26 2017-01-27 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
CN107428820B (zh) * 2014-11-19 2022-03-22 阿克松神经系统科学公司 在阿尔茨海默氏病中的人源化tau抗体
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP6793134B2 (ja) 2015-06-05 2020-12-02 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
MA42377A (fr) 2015-07-06 2018-05-16 Ucb Biopharma Sprl Anticorps se liant à tau
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201518675D0 (en) * 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
SG11201808434WA (en) 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
KR101997319B1 (ko) * 2016-06-21 2019-07-08 전남대학교산학협력단 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
FR3058143B1 (fr) 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MY198942A (en) 2016-12-07 2023-10-03 Genentech Inc Anti-tau antibodies and methods of use
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
WO2018117647A1 (ko) * 2016-12-21 2018-06-28 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
SG11201907927SA (en) * 2017-03-28 2019-10-30 Janssen Vaccines & Prevention Bv Binding molecules that specifically bind to tau
WO2018195376A1 (en) * 2017-04-21 2018-10-25 Ohio University Peptide-based inhibitors of mark family proteins
CN110881274B (zh) * 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
JP7029718B2 (ja) * 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
JP6979533B2 (ja) 2017-10-02 2021-12-15 ブラックソーン セラピューティクス インコーポレイテッド 対象における神経行動学的表現型を検知、診断、予測、予知、または処置するための方法及びツール
WO2019077500A1 (en) * 2017-10-16 2019-04-25 Eisai R&D Management Co., Ltd. ANTI-WATER ANTIBODIES AND USES THEREOF
TWI827557B (zh) * 2017-10-25 2024-01-01 美商健生醫藥公司 Ｔａｕ胜肽之組成物及其用途
SG11202003624SA (en) * 2017-10-27 2020-05-28 United Neuroscience Tau peptide immunogen constructs
WO2019120527A1 (en) * 2017-12-20 2019-06-27 Michael Heneka Novel means and methods for treating neurodegenerative diseases
CA3090356A1 (en) 2018-03-11 2019-09-19 Koorosh Shahpasand Conformation-independent antibodies against neurotoxic tau proteins
RU2020135052A (ru) * 2018-03-28 2022-04-29 Аксон Ньюросайенс Се Способы выявления и лечения болезни альцгеймера на основе антител
RU2679059C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
US11085935B2 (en) 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
AU2019262220B2 (en) * 2018-05-03 2025-10-16 Washington University Methods of diagnosing and treating based on site-specific tau phosphorylation
CR20210178A (es) * 2018-07-03 2021-05-11 Hoffmann La Roche OLIGONUCLEÓTIDOS PARA MODULAR LA EXPRESIÓN DE TAU (Divisional 2021-0058)
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
JP7623699B2 (ja) * 2018-11-08 2025-01-29 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
EP3883602A4 (en) * 2018-11-19 2023-04-12 The Board Of Regents Of The University Of Texas System TAU PEPTIDE ANTIGENS AND ANTIBODIES BINDING TO THEM FOR THE TREATMENT OF TAUOPATHIES
WO2020120644A1 (en) * 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
CN119954947A (zh) * 2019-02-08 2025-05-09 普罗塞纳生物科学有限公司 识别Tau的抗体
EP3920966A2 (en) 2019-02-08 2021-12-15 AC Immune S.A. Method of safe administration of phosphorylated tau peptide vaccine
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
JP2022526334A (ja) * 2019-03-25 2022-05-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新たなタウ種を標的化することによるタウオパチー障害の処置の方法
BR112021021213A2 (pt) * 2019-04-24 2021-12-21 Ac Immune Sa Administração heteróloga de vacinas de tau
EP3977135A1 (en) * 2019-05-31 2022-04-06 Eli Lilly And Company Compounds and methods targeting human tau
GB201909393D0 (en) 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
WO2021024209A1 (en) * 2019-08-06 2021-02-11 Aprinoia Therapeutics Inc. Antibodies that bind to pathological tau species and uses thereof
CN114555631A (zh) * 2019-08-13 2022-05-27 华盛顿大学 检测MTBR tau同种型的方法及其用途
JP7576335B2 (ja) * 2019-08-15 2024-10-31 学校法人東京医科大学 Ｃｌｓｐ阻害物質による影響を受けないｃｌｓｐ誘導体及びｃｌｓｐ活性の増強／保護剤
US20220402979A1 (en) * 2019-09-09 2022-12-22 Axon Neuroscience Se Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
US12493043B2 (en) 2019-09-10 2025-12-09 Washington University Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation
JOP20220092A1 (ar) * 2019-10-22 2023-01-30 Biogen Ma Inc جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
IL270800A (en) * 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
CN110841059A (zh) * 2019-12-03 2020-02-28 南通大学 老年性痴呆小鼠模型的制备方法
CA3168823A1 (en) * 2020-02-05 2021-08-12 Sumitomo Pharma Co., Ltd. Determination agent and determination method for tauopathy and dementia-related diseases
AU2021276401A1 (en) * 2020-05-19 2022-12-15 Othair Prothena Limited Multi-epitope vaccine for the treatment of Alzheimer's disease
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
US20230302127A1 (en) * 2020-08-07 2023-09-28 Othair Prothena Limited Tau vaccine for the treatment of alzheimer's disease
EP4192497A4 (en) * 2020-08-07 2024-08-21 Othair Prothena Limited MULTI-EPITOPIC VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP4252243A2 (en) 2020-11-30 2023-10-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
IL303737A (en) * 2020-12-18 2023-08-01 Sangamo Therapeutics Inc Improved pharmaceutical compositions containing adeno-associated viral vector
TW202246320A (zh) * 2021-02-14 2022-12-01 愛爾蘭商普羅帝納生物科學公司 使用識別ｔａｕ之抗體之方法
KR20230147034A (ko) * 2021-02-19 2023-10-20 에자이 알앤드디 매니지먼트 가부시키가이샤 항-pt217 타우 항체
EP4297868A4 (en) 2021-02-23 2025-01-08 Hoth Therapeutics, Inc. USE OF APREPITANT TO TREAT ALZHEIMER'S
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
CN113430230A (zh) * 2021-06-24 2021-09-24 南通大学 tau截断体蛋白在诱导tau病理聚集中的应用
WO2023060278A2 (en) * 2021-10-08 2023-04-13 Tiberias Technology (Hk) Limited Tibtech methods and compositions for detecting cdh17
CN113861441A (zh) * 2021-10-28 2021-12-31 南开大学 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN116554342A (zh) * 2022-01-29 2023-08-08 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物
AU2023342086A1 (en) 2022-09-15 2025-03-13 Voyager Therapeutics, Inc. Tau binding compounds
WO2025019332A1 (en) * 2023-07-14 2025-01-23 Alzpath, Inc. Methods for remote blood collection, extraction and analysis of neuro biomarkers
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations
CN117624354B (zh) * 2023-11-30 2024-07-12 无锡傲锐东源生物科技有限公司 一种抗人乙酰化tau281兔单克隆抗体及其应用
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JP3127158B2 (ja) 1989-10-05 2001-01-22 オプテイン，インコーポレイティド 新規の遺伝子及びポリペチドの無細胞合成並びに単離
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DK0618968T3 (da) * 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
JPH09501936A (ja) 1993-08-26 1997-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
DE69535901D1 (de) 1994-10-28 2009-01-29 Max Planck Gesellschaft Proteinkinase npk-110
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5643207A (en) 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
AU705688B2 (en) 1995-11-10 1999-05-27 Cytogen Corporation Peptides which enhance transport across tissues and methods of identifying and using the same
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
US6198966B1 (en) 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
JP3383618B2 (ja) 1999-08-18 2003-03-04 松下電器産業株式会社 移動体通信端末装置及び受信強度検出方法
AU7263600A (en) * 1999-09-09 2001-04-10 Mcgill University Diagnosis, prognosis and treatment of trinucleotide repeat-associated diseases and intranuclear inclusions-associated diseases
AU7653100A (en) * 1999-09-09 2001-04-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. A minimal tau peptide for the nucleation of paired helical filaments
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
ES2276732T3 (es) 2001-09-03 2007-07-01 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Mimotopos de antigenos y vacuna contra enfermedades cancerosas.
TWI226905B (en) 2001-10-19 2005-01-21 Bioware Technology Co Ltd Low pressure-accelerated particle gene gun
AU2003246664B2 (en) * 2002-07-12 2007-06-14 Axon Neuroscience Se Transgenic animal expressing Alzheimer's tau protein
AU2003250102B2 (en) * 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
EP1516930A1 (en) 2003-09-16 2005-03-23 Georg-August Universität Göttingen Cellular model of tauopathies for lead identification and drug discovery
US20050142609A1 (en) 2003-10-08 2005-06-30 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
ATE524487T1 (de) 2007-01-11 2011-09-15 Univ Ramot Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen
US8106015B2 (en) * 2007-04-20 2012-01-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing immune response with peptide
US20110212075A1 (en) * 2007-06-25 2011-09-01 Siemens Aktiengesellschaft Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US8748386B2 (en) 2009-06-10 2014-06-10 New York University Immunological targeting of pathological Tau proteins
AU2010286501B2 (en) * 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
WO2011053565A2 (en) * 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
MX2012005300A (es) * 2009-11-06 2012-07-30 David Gladstone Inst Metodos y composiciones para modula niveles de tau.
CA2780678A1 (en) * 2009-11-19 2011-05-26 Ou Solis Biodyne Compositions for increasing polypeptide stability and activity, and related methods
CL2010000019A1 (es) * 2010-01-11 2010-06-11 Univ Chile Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
IL287794A (en) 2022-01-01
MX391157B (es) 2025-03-21
HRP20180083T8 (hr) 2018-07-27
US9518101B2 (en) 2016-12-13
RU2018102103A3 (OSRAM) 2021-05-31
JP2017093470A (ja) 2017-06-01
CA2848346A1 (en) 2013-03-28
US9845352B2 (en) 2017-12-19
RU2018102103A (ru) 2019-02-21
ZA201401333B (en) 2015-09-30
WO2013041962A1 (en) 2013-03-28
BR112014006376B1 (pt) 2021-07-27
AU2020200624A9 (en) 2021-12-23
JP6499345B2 (ja) 2019-04-10
IL231201B (en) 2018-06-28
IL259775A (en) 2018-07-31
US20150050215A1 (en) 2015-02-19
SG11201400125RA (en) 2014-03-28
TR201800669T4 (tr) 2018-03-21
SG10201703771WA (en) 2017-06-29
EP2758433B1 (en) 2017-10-18
HUE036177T2 (hu) 2018-06-28
IL259775B (en) 2020-05-31
KR20210099167A (ko) 2021-08-11
JP2018117631A (ja) 2018-08-02
IL274440A (en) 2020-06-30
CL2016000215A1 (es) 2017-08-18
JP2018183160A (ja) 2018-11-22
JP6286590B2 (ja) 2018-02-28
AU2012311234B2 (en) 2017-09-28
US11098106B2 (en) 2021-08-24
EP3275461A1 (en) 2018-01-31
US20170145082A1 (en) 2017-05-25
LT2758433T (lt) 2018-02-12
JP2017042172A (ja) 2017-03-02
JP6360869B2 (ja) 2018-07-18
KR102285743B1 (ko) 2021-08-06
IL231201A0 (en) 2014-04-30
US12404322B2 (en) 2025-09-02
AU2020200624B2 (en) 2021-12-23
SG10201912964PA (en) 2020-02-27
JP2014530597A (ja) 2014-11-20
AU2017272259A1 (en) 2018-01-04
CN109265543A (zh) 2019-01-25
MX2014003357A (es) 2015-03-20
JP7182316B2 (ja) 2022-12-02
US20220010004A1 (en) 2022-01-13
CL2015001314A1 (es) 2015-09-21
RU2645259C2 (ru) 2018-02-19
CN104185640B (zh) 2018-07-20
CN104185640A (zh) 2014-12-03
JP6253583B2 (ja) 2017-12-27
KR20200084362A (ko) 2020-07-10
CY1119792T1 (el) 2018-06-27
JP6950981B2 (ja) 2021-10-20
CN109265543B (zh) 2022-04-26
SMT201800109T1 (it) 2018-05-02
JP2022031631A (ja) 2022-02-22
ES2656442T3 (es) 2018-02-27
US9828421B2 (en) 2017-11-28
AU2012311234A1 (en) 2014-05-01
RU2014115481A (ru) 2015-10-27
HK1199459A1 (en) 2015-07-03
ME03008B (me) 2018-10-20
IL274440B (en) 2021-12-01
AU2017272259B2 (en) 2019-11-14
PT2758433T (pt) 2018-01-19
KR20140063853A (ko) 2014-05-27
AU2020200624A1 (en) 2020-02-20
EP2758433A1 (en) 2014-07-30
UA123390C2 (uk) 2021-03-31
US20170260263A1 (en) 2017-09-14
US20180282401A1 (en) 2018-10-04
SI2758433T1 (en) 2018-02-28
UA115657C2 (uk) 2017-12-11
JP2020072675A (ja) 2020-05-14
DK2758433T3 (en) 2018-01-15
HRP20180083T1 (hr) 2018-02-23
CL2014000679A1 (es) 2014-11-21
PL2758433T3 (pl) 2018-06-29
CN115417916A (zh) 2022-12-02
MY183989A (en) 2021-03-17
SG10201912955PA (en) 2020-02-27
JP6637124B2 (ja) 2020-01-29
KR102130439B1 (ko) 2020-07-07
BR112014006376A2 (pt) 2017-06-13
RS56852B1 (sr) 2018-04-30

Similar Documents

Publication Publication Date Title
MY183989A (en) Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
PH12013500615A1 (en) Phosphospecific antibodies recognising tau
MX356800B (es) Anticuerpo tau humanizado.
WO2010115843A3 (en) Pharmaceutical composition
MX2019008758A (es) Anticuerpos anti-cd37 y usos de los mismos.
GEP20125385B (en) Antibodies directed against amyloid-beta peptide and methods using same
WO2019186276A8 (en) Antibody-based methods of detecting and treating alzheimer's disease
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MX2021001098A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
WO2016012285A3 (en) Method
WO2014007982A3 (en) C-terminal and central epitope a-beta antibodies
PH12014502582B1 (en) Anti-TG2 Antibodies and Methods for Using the Same
UA102368C2 (ru) СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА
EA201491324A1 (ru) Средства и методы лечения или диагностики раковых заболеваний с мутацией r132h в гене idh1
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies
WO2009120659A3 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents
MY158954A (en) Antibodies that recognize sulphatides and sulphated proteoglycans and the use
TH95385B (th) แอนติบอดีที่ได้รับการฮิวมาไนซ์
WO2009120657A3 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents

Legal Events

Date Code Title Description
FG Grant or registration